drug delivery

News

Dose-at-home Leqembi for Alzheimer's cleared in US

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

Patients

Jonah Comstock at AAPS interviewing Mehul Desai

Challenging conventional wisdom on injectables, with Mehul D...

Mehul Desai, VP of medical affairs at Enable Injections, sat down with pharmaphorum editor-in-chief Jonah Comstock at AAPS.

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

News

MSD says subcutaneous Keytruda matches IV form

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.

Dose-at-home Leqembi for Alzheimer's cleared in US

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Challenging conventional wisdom on injectables, with Mehul D...

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

MSD says subcutaneous Keytruda matches IV form

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

drug delivery

Editor's Picks